AU2002320140B2 - Method for enhancing the effectiveness of cancer therapies - Google Patents
Method for enhancing the effectiveness of cancer therapies Download PDFInfo
- Publication number
- AU2002320140B2 AU2002320140B2 AU2002320140A AU2002320140A AU2002320140B2 AU 2002320140 B2 AU2002320140 B2 AU 2002320140B2 AU 2002320140 A AU2002320140 A AU 2002320140A AU 2002320140 A AU2002320140 A AU 2002320140A AU 2002320140 B2 AU2002320140 B2 AU 2002320140B2
- Authority
- AU
- Australia
- Prior art keywords
- carbohydrate
- patient
- modified pectin
- galectin
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 44
- 230000002708 enhancing effect Effects 0.000 title claims description 8
- 238000011275 oncology therapy Methods 0.000 title description 5
- 239000001814 pectin Substances 0.000 claims description 35
- 229920001277 pectin Polymers 0.000 claims description 35
- 235000010987 pectin Nutrition 0.000 claims description 35
- 102000007563 Galectins Human genes 0.000 claims description 34
- 108010046569 Galectins Proteins 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 33
- 150000001720 carbohydrates Chemical class 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 25
- 102000000802 Galectin 3 Human genes 0.000 claims description 24
- 108010001517 Galectin 3 Proteins 0.000 claims description 24
- 238000001356 surgical procedure Methods 0.000 claims description 12
- 238000002512 chemotherapy Methods 0.000 claims description 11
- 229930182830 galactose Natural products 0.000 claims description 7
- 102000000795 Galectin 1 Human genes 0.000 claims description 6
- 108010001498 Galectin 1 Proteins 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 4
- 229920002230 Pectic acid Polymers 0.000 claims description 4
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000010318 polygalacturonic acid Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 description 55
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 230000006907 apoptotic process Effects 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 230000033115 angiogenesis Effects 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000011443 conventional therapy Methods 0.000 description 4
- 229940045109 genistein Drugs 0.000 description 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 4
- 235000006539 genistein Nutrition 0.000 description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 4
- 230000008611 intercellular interaction Effects 0.000 description 4
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 235000021309 simple sugar Nutrition 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000025164 anoikis Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000000069 breast epithelial cell Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000032341 cell morphogenesis Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 108010038196 saccharide-binding proteins Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- -1 pectins Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29999101P | 2001-06-21 | 2001-06-21 | |
| US60/299,991 | 2001-06-21 | ||
| US10/176,235 US6680306B2 (en) | 2001-06-21 | 2002-06-20 | Method for enhancing the effectiveness of cancer therapies |
| US10/176,235 | 2002-06-20 | ||
| PCT/US2002/019885 WO2003000118A2 (en) | 2001-06-21 | 2002-06-21 | Method for enhancing the effectiveness of cancer therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002320140A1 AU2002320140A1 (en) | 2003-06-19 |
| AU2002320140B2 true AU2002320140B2 (en) | 2007-11-29 |
Family
ID=26872020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002320140A Ceased AU2002320140B2 (en) | 2001-06-21 | 2002-06-21 | Method for enhancing the effectiveness of cancer therapies |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6680306B2 (https=) |
| EP (1) | EP1406639A4 (https=) |
| JP (1) | JP2004535430A (https=) |
| CN (1) | CN100558367C (https=) |
| AU (1) | AU2002320140B2 (https=) |
| BR (1) | BR0210550A (https=) |
| CA (1) | CA2451841A1 (https=) |
| CZ (1) | CZ200487A3 (https=) |
| IL (1) | IL159461A0 (https=) |
| MX (1) | MXPA03012021A (https=) |
| WO (1) | WO2003000118A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072085A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20030004132A1 (en) * | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
| US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US20040121981A1 (en) * | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| US20040259816A1 (en) * | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| WO2004091634A1 (en) * | 2003-04-07 | 2004-10-28 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| US20050043272A1 (en) * | 2003-07-11 | 2005-02-24 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
| DE10335236B3 (de) * | 2003-08-01 | 2005-02-24 | Drägerwerk AG | Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom |
| US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US20050282773A1 (en) * | 2004-01-14 | 2005-12-22 | Pro-Pharmaceuticals, Inc. | Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer |
| WO2005079314A2 (en) * | 2004-02-13 | 2005-09-01 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
| WO2005095463A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| US20060074050A1 (en) * | 2004-07-14 | 2006-04-06 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
| EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
| KR20070104673A (ko) * | 2005-03-23 | 2007-10-26 | 화이자 프로덕츠 인코포레이티드 | 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법 |
| US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
| WO2009018447A2 (en) * | 2007-07-31 | 2009-02-05 | New York University | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
| WO2011060272A2 (en) * | 2009-11-13 | 2011-05-19 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
| CA2858601C (en) * | 2011-12-08 | 2020-11-17 | Isaac Eliaz | Reduction of galectin-3 levels by plasmapheresis |
| AU2012363033B2 (en) | 2011-12-28 | 2016-06-02 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
| WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| ES2848538T3 (es) | 2012-06-06 | 2021-08-10 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible |
| DK2900061T3 (da) | 2012-09-17 | 2020-03-02 | Galectin Therapeutics Inc | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA2930817A1 (en) | 2013-11-17 | 2015-05-21 | Rdd Pharma Ltd. | Methods for treating radiation induced gastrointestinal tract injury |
| AU2017327392B9 (en) | 2016-09-13 | 2023-10-12 | Tiziana Life Sciences Plc | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| CA3062648A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| US5895784A (en) * | 1994-07-07 | 1999-04-20 | Michigan Cancer Foundation | Method for treatment of cancer by oral administration of modified pectin |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US107222A (en) * | 1870-09-13 | Improvement in machines for tenoning window-sash | ||
| US5843442A (en) | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
| US5639737A (en) | 1991-11-04 | 1997-06-17 | Co Enzyme Technology Ltd. | Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors |
| US20020107222A1 (en) | 1993-03-01 | 2002-08-08 | David Platt | Modified polysaccharides for treatment of cancer |
| US5490911A (en) * | 1993-11-26 | 1996-02-13 | The United States Of America As Represented By The Department Of Energy | Reactive multilayer synthesis of hard ceramic foils and films |
| US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5681923A (en) | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
| EP0888776A4 (en) * | 1996-03-15 | 2005-01-26 | Takara Bio Inc | PRODUCT OBTAINED BY THERMAL TREATMENT OF URONIC ACID, AND FOOD, BEVERAGES OR MEDICAMENTS CONTAINING THE SAME |
| US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
| JP2001519366A (ja) * | 1997-10-15 | 2001-10-23 | ポーラクス バイオファーマシュティカルズ，インコーポレーテッド | ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法 |
| US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
| US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| US6274566B1 (en) * | 1999-02-23 | 2001-08-14 | Econugenics, Inc. | Methods for treating mammals with modified alginates and pectins |
| EP1363673A2 (en) | 2000-09-25 | 2003-11-26 | Pro-Pharmaceuticals, Inc. | Compositions for reducing side effects in chemotherapeutic treatments |
| US20020104222A1 (en) * | 2001-02-06 | 2002-08-08 | Jay Larry Dean | Knife for removing the hide of an animal and method therefor |
| US6914055B2 (en) * | 2001-03-27 | 2005-07-05 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6645946B1 (en) * | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| ES2376739T3 (es) | 2001-03-27 | 2012-03-16 | Galectin Therapeutics Inc. | Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer |
| US6982255B2 (en) * | 2001-03-27 | 2006-01-03 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| US20060074050A1 (en) * | 2004-07-14 | 2006-04-06 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
-
2002
- 2002-06-20 US US10/176,235 patent/US6680306B2/en not_active Expired - Fee Related
- 2002-06-21 IL IL15946102A patent/IL159461A0/xx unknown
- 2002-06-21 CZ CZ200487A patent/CZ200487A3/cs unknown
- 2002-06-21 EP EP02749641A patent/EP1406639A4/en not_active Withdrawn
- 2002-06-21 JP JP2003506572A patent/JP2004535430A/ja active Pending
- 2002-06-21 CN CNB028160037A patent/CN100558367C/zh not_active Expired - Fee Related
- 2002-06-21 BR BR0210550-0A patent/BR0210550A/pt not_active IP Right Cessation
- 2002-06-21 AU AU2002320140A patent/AU2002320140B2/en not_active Ceased
- 2002-06-21 CA CA002451841A patent/CA2451841A1/en not_active Abandoned
- 2002-06-21 MX MXPA03012021A patent/MXPA03012021A/es not_active Application Discontinuation
- 2002-06-21 WO PCT/US2002/019885 patent/WO2003000118A2/en not_active Ceased
-
2003
- 2003-04-07 US US10/408,723 patent/US20040023925A1/en not_active Abandoned
- 2003-09-08 US US10/657,383 patent/US20040043962A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| US5895784A (en) * | 1994-07-07 | 1999-04-20 | Michigan Cancer Foundation | Method for treatment of cancer by oral administration of modified pectin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1543351A (zh) | 2004-11-03 |
| EP1406639A4 (en) | 2004-07-28 |
| CN100558367C (zh) | 2009-11-11 |
| IL159461A0 (en) | 2004-06-01 |
| US20040023925A1 (en) | 2004-02-05 |
| MXPA03012021A (es) | 2004-06-03 |
| US20040043962A1 (en) | 2004-03-04 |
| EP1406639A2 (en) | 2004-04-14 |
| US6680306B2 (en) | 2004-01-20 |
| WO2003000118A2 (en) | 2003-01-03 |
| BR0210550A (pt) | 2004-05-25 |
| WO2003000118A3 (en) | 2003-04-10 |
| JP2004535430A (ja) | 2004-11-25 |
| CA2451841A1 (en) | 2003-01-03 |
| US20030013681A1 (en) | 2003-01-16 |
| CZ200487A3 (cs) | 2004-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002320140B2 (en) | Method for enhancing the effectiveness of cancer therapies | |
| AU2002320140A1 (en) | Method for enhancing the effectiveness of cancer therapies | |
| Ciccone et al. | Bemiparin, an effective and safe low molecular weight heparin: a review | |
| Heist et al. | Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer | |
| JP5484320B2 (ja) | ナリンゲニンとナリンジンを形質転換成長因子−β１のシグナル経路阻害剤とする使用 | |
| EP3042669A1 (en) | Antitumor agent and antitumor effect enhancer | |
| CN100558368C (zh) | 化合物在制备用于治疗免疫性疾病的药物中的用途 | |
| CN108186643B (zh) | 一种具有协同抗骨肉瘤功效的药物组合物及其应用 | |
| EP2732044B1 (en) | Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| AU2016330332A1 (en) | An anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof | |
| KR20100107461A (ko) | 의약 조성물 또는 조합제 | |
| WO2009033047A2 (en) | Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan | |
| IL131096A0 (en) | Muscle-derived compositions | |
| WO2000056334A1 (en) | Use of imino sugars for anti-tumor therapy | |
| EP4115902A1 (en) | Combined use of ctb006 and ponatinib | |
| CN110876803B (zh) | 一种包含乳蛋白和油酸的药物组合物 | |
| RU2804771C1 (ru) | Комплексное антиангиогенное и гипоксия-ориентированное противоопухолевое средство | |
| US10328056B2 (en) | Priming of pancreatic tumor cells and cancer stem cells to TRAIL-induced apoptosis | |
| Simka et al. | Anti-metastatic activities of heparins | |
| Uhlenbruck et al. | Prevention of experimental liver metastases by D-galactose | |
| KR102065150B1 (ko) | 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
| WO2015184248A1 (en) | Methods of treating fibrotic diseases | |
| CN112168960A (zh) | 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用 | |
| WESSELS et al. | IN VIVO POTENTIATION OF c/s-DIAMMINEDICHLOROPLATINUM (II) ANTITUMOR ACTIVITY BY PRETREATMENT WITH SPARSOMYCIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND CO-INVENTOR NAMES FROM CHANG, YANG TO CHANG, YAN AND SASEK, VODEK TO SASAK, VODEK |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: PROSPECT THERAPEUTICS, INC. Free format text: FORMER APPLICANT(S): GLYCOGENESYS, INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |